208 related articles for article (PubMed ID: 15550579)
1. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
; Pagani O; Gelber S; Price K; Zahrieh D; Gelber R; Simoncini E; Castiglione-Gertsch M; Coates AS; Goldhirsch A
Ann Oncol; 2004 Dec; 15(12):1749-59. PubMed ID: 15550579
[TBL] [Abstract][Full Text] [Related]
2. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
4. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Zhou WB; Ding Q; Chen L; Liu XA; Wang S
Breast Cancer Res Treat; 2011 Aug; 128(3):625-31. PubMed ID: 21553116
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
6. Toremifene versus tamoxifen for advanced breast cancer.
Mao C; Yang ZY; He BF; Liu S; Zhou JH; Luo RC; Chen Q; Tang JL
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD008926. PubMed ID: 22786516
[TBL] [Abstract][Full Text] [Related]
7. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.
Kimura M; Tominaga T; Kimijima I; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Breast Cancer; 2014 May; 21(3):275-83. PubMed ID: 22968626
[TBL] [Abstract][Full Text] [Related]
9. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
Gianni L; Gelber S; Ravaioli A; Price KN; Panzini I; Fantini M; Castiglione-Gertsch M; Pagani O; Simoncini E; Gelber RD; Coates AS; Goldhirsch A
Eur J Cancer; 2009 Mar; 45(4):561-71. PubMed ID: 19062268
[TBL] [Abstract][Full Text] [Related]
10. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
11. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
[TBL] [Abstract][Full Text] [Related]
12. Phase III trials of toremifene vs tamoxifen.
Gams R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):23-8. PubMed ID: 9165503
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
14. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
17. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
[TBL] [Abstract][Full Text] [Related]
18. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.
Wiseman LR; Goa KL
Drugs; 1997 Jul; 54(1):141-60. PubMed ID: 9211086
[TBL] [Abstract][Full Text] [Related]
19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
